GlassScriptPhysician profile
Allan M Wohl
NPI 1437199734
$8,971.96
in general payments reported to CMS, 2019-2025
41 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $346 · 2021: $970 · 2022: $1,464 · 2023: $1,890 · 2024: $1,580 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,816 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,816.04 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.11 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,001.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $895.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $642.53 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $628.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $508.00 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $431.05 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.54 | 2019-2025 | Jardiance |
| Pfizer INC. | $349.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.10 | 2021-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $300.00 | 2019 | |
| Abbott Laboratories | $231.02 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $198.63 | 2022-2025 | |
| Astellas Pharma US INC | $193.54 | 2021-2025 | Veozah |
| Axsome Therapeutics, INC. | $191.80 | 2023-2025 | Auvelity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $184.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $173.09 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Exact Sciences Corporation | $168.61 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $152.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $140.52 | 2019-2022 | |
| Dexcom, INC. | $117.15 | 2022-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $89.10 | 2024-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $70.58 | 2020-2021 | |
| Corcept Therapeutics | $67.79 | 2023-2024 | Korlym |
| Edwards Lifesciences Corporation | $66.30 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Idorsia Pharmaceuticals US INC | $62.06 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $50.96 | 2022-2024 | Abilify Mycite |
| Lundbeck LLC | $39.18 | 2023-2024 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $37.05 | 2022-2023 | Prehevbrio |
| Janssen Pharmaceuticals, INC | $35.40 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.51 | 2025 | Caplyta |
| Alexion Pharmaceuticals, INC. | $31.28 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.25 | 2022-2025 | Zoryve |
| Althera Pharmaceuticals LLC | $26.95 | 2021-2022 | |
| Inspire Medical Systems, INC. | $20.56 | 2025 | Inspire |
| Endo Pharmaceuticals INC. | $18.00 | 2022 | |
| Optos, INC. | $16.52 | 2020 | |
| Acadia Pharmaceuticals INC | $15.61 | 2025 | Daybue |
| Paratek Pharmaceuticals, INC. | $15.23 | 2024 | Nuzyra |
| Sanofi Pasteur INC. | $14.68 | 2019 | |
| Eisai INC. | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Wohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.